GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Study Links Higher Triglyceride-Glucose Index to Increased Risk of Chronic Complications in Type 2 Diabetes

by GOAI
Share To

A recent study published in *BMC Endocrine Disorders* has identified a significant link between the triglyceride-glucose index (TyG index) and chronic complications in individuals with type 2 diabetes mellitus (T2DM). The research, led by Wang et al., examined how the TyG index—a marker derived from fasting triglyceride and glucose levels—can serve as an indicator for assessing the risk of long-term complications associated with T2DM. As diabetes remains a pressing global health issue, this study provides new insights into potential tools for monitoring and managing its effects.

The researchers analyzed data to explore the relationship between the TyG index and various chronic conditions commonly seen in patients with T2DM. Their findings suggest that higher TyG index values correlate with an increased likelihood of developing complications such as cardiovascular disease, kidney dysfunction, and nerve damage. By focusing on this specific biomarker, the study highlights its potential utility in identifying at-risk individuals early on. The results underscore the importance of further investigation into how metabolic markers like the TyG index can contribute to more effective management strategies for diabetes-related health challenges.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top